Overview of the human reproductive technologies market
The World Health Organization (WHO) reported in 2010 that almost 1.9% of the global female population between the age of 20 years and 44 years were unable to conceive their first child, while 10.9% of the women who had already given birth to a child faced problems conceiving the subsequent time. The globally increasing prevalence of infertility will propel the global human reproductive technologies market substantially.
Based on geography, the global human reproductive technologies market can be segmented into North America, Europe, Asia Pacific, and Rest of the World (RoW). Among the key geographic segments, North America dominates the market, followed by Europe. High incidence of obesity, paradigm shift in lifestyle choices, and increasing age of conception are key factors driving the human reproductive technologies market in North America.
Browse Market Research Report:
Human reproductive technologies include procedures and therapies for conceiving or controlling pregnancy by means of artificial and/or semi artificial medical solutions. Reproductive technologies are used to treat infertility problems in males as well as in females. Since the last decade, a remarkable prevalence of infertility has been observed worldwide and its morbidity rate is rapidly growing. Changes in lifestyle such as delay in bearing the first child, use of contraceptive pills, increased alcohol consumption and smoking are some of the factors leading to increase in the infertility rate globally, due to which the human reproductive technologies market is experiencing rise in demand. The World Health Organization (WHO) reported that in 2010, approximately 1.9% of women aged between 20 years and 44 years were unable to have their first child and 10.5% of women who had already conceived were unable to conceive for the subsequent times. Thus, high global infertility rates will continue to provide newer growth opportunities to this market. Some other factors contributing to the growth of the human reproductive technologies market include increasing morbidity rate of infertility in both males and females, rise in awareness about the available technologies for treating problems related to reproduction, rising prevalence of unwanted pregnancies, and overall advancement in the available technologies to control reproduction.
Human reproductive technologies are mainly categorized on the basis of infertility treatments and contraceptive technologies. The infertility drugs market is analyzed based on the big seven brands (by sales) such as, Gonal-f, Follistim AQ, AndroGel, Testim, Viagra, Cialis and Levitra/Staxyn. Viagra, Gonal-f and AndroGel are the major drugs in their respective drug classes, which are preferred majorly for treating different causes of infertility. Further, the human reproductive technologies market is analyzed by various infertility treatment procedures which is led by the intrauterine insemination (IUI) procedure owing to low procedural cost and less complexity in performing the procedure.
Fill the form for an exclusive sample of this report: